After discussing GW's progress with Epidiolex reimbursement/access and other key commercial considerations with the company's VP of Investor Relations, Stifel analyst Paul Matteis said he continues to recommend GW Pharmaceuticals shares ahead of what he believes will be a very strong launch for Epidiolex with upside to 2019 consensus expectations. Matteis, who warns that a "collection of variables may create a disconnect where recognized sales are not really indicative of how the launch is progressing" in the company's Q4 results, keeps a Buy rating and $179 price target on GW Pharmaceuticals shares.